These findings suggest that in established coronary artery disease, Lp(a) drives ASCVD-risk by promoting progression of vulnerable plaque phenotypes, providing a potential mechanistic explanation for the association between Lp(a) and clinical atherothrombotic events. Here, LPA is linked to atherosclerosis.